Skip to content

dr. Snauwaert Sylvia

Hematologie
contactgegevens
Geen artikels gevonden...
06/12/2023
Hematologie

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.

Blood 2022 Apr 14;139(15):2338-2346. doi: 10.1182/blood.2021013526. -PMID: 34936697 DOI: 10.1182/blood.2021013526dr. Snauwaert Sylvia
06/12/2023
Hematologie

High total metabolic tumor volume at baseline predicts survival independent of response to therapy.

Blood. 2020 Apr 16;135(16):1396-1405. doi: 10.1182/blood.2019003526.PMID: 31978225 Free PMC article. Clinical Trial.dr. Snauwaert Sylvia
04/01/2020
Hematologie

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

Br J Haematol. 2020 Apr;189(1):84-96. doi: 10.1111/bjh.16300. Epub 2019 Nov 8.PMID: 31702836 Free PMC article.dr. Snauwaert Sylvia
05/01/2020
Hematologie

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment.

Haematologica. 2020 May;105(5):1306-1316. doi: 10.3324/haematol.2019.222612. Epub 2019 Aug 1.PMID: 31371409 Free PMC articledr. Snauwaert Sylvia
03/01/2019
Hematologie

Guidelines of the Belgian Hematology Society on the use of stem cell transplantation in lymphoproliferative diseases.

Belgian journal of hematology volume 10 issue 2 march 2019 p 69-79.dr. Snauwaert Sylvia
11/08/2019
Hematologie

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

Br J Haematol. 2019 Nov 8. doi: 10.1111/bjh.16300. PMID: 31702836dr. Snauwaert Sylvia
08/01/2019
Hematologie

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment.

Haematologica. 2019 Aug 1. pii: haematol.2019.222612. doi: 10.3324/haematol.2019.222612. PMID: 31371409dr. Snauwaert Sylvia
08/01/2019
Hematologie

Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.

Lancet Haematol. 2019 Aug;6(8):e429-e437. doi: 10.1016/S2352-3026(19)30089-4. Epub 2019 Jul 8. PMID: 31296423dr. Snauwaert Sylvia
01/01/2018
Inwendige Ziekten

Hodgkin’s lymphoma: Belgian Hematology Society guidelines in diagnosis, treatment and follow-up.

Belgian Journal of Hematology. 2018; 9; 214-224.dr. Snauwaert Sylviadr. De Wilde Vincent
02/01/2018
Inwendige Ziekten

Highlights in lymphoma.

Belgian Journal of Hematology. 2018 Feb; 9(1): 14-18.dr. Snauwaert Sylvia
Hematologie

Neuropathie, longinfecties en andere ernstige complicaties bij multiple myeloom en Waldenström.

dr. Snauwaert Sylvia
Hematologie

T-cell lymphoma.

Brussel2022-03-26dr. Snauwaert Sylvia
Hematologie

Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study.

2022-01-01dr. Snauwaert Sylvia
Hematologie

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”.

2022-01-01dr. Snauwaert Sylvia
Hematologie

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial.

2022-01-01dr. Snauwaert Sylvia
Hematologie

EFFECTIVENESS AND SAFETY OF IBRUTINIB IN WALDENSTRÖM’S MACROGLOBULINEMIA (WM) IN BELGIAN ROUTINE CLINICAL PRACTICE WITH A 3-YEAR FOLLOW-UP.

2022-01-01dr. Snauwaert Sylvia
Hematologie

Effectiveness and Safety of Ibrutinib in Patients with Mantle Cell Lymphoma (MCL) in Belgian Routine Clinical Practice: 3-Year Follow-up.

2022-01-01dr. Snauwaert Sylvia
Hematologie

EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MANTLE CELL LYMPHOMA (MCL) IN BELGIAN ROUTINE CLINICAL PRACTICE WITH A 3-YEAR FOLLOW-UP.

Poster at virtual EHA 20212021-09-06dr. Snauwaert Sylvia
Hematologie

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study.

ASH 20202020-01-01dr. Snauwaert Sylvia
Hematologie

Final Analysis of the International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL in Response after R-CHOP.

Poster at ASH;2020-12-06dr. Snauwaert Sylvia
Hematologie

TARP AS IMMUNOTHERAPEUTIC TARGET IN AML EXPRESSED IN THE LSC COMPARTMENT.

EHA Library. Depreter B. 06/14/19; 265994; PF204. Poster at EHA 2019.2019-01-01dr. Snauwaert Sylvia
Hematologie

Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study.

Poster At ASH 20182018-01-01dr. Snauwaert Sylvia
Hematologie

Galapagos project: samenwerking met reumatologie: Bloody issues in RA. Hematologische problemen bij patiënten met reumatoïde arthritis.

2020-12-14dr. Snauwaert Sylvia
Hematologie

Urgenties in de hematologie.

2020-10-07dr. Snauwaert Sylvia
Hematologie

Young hematology education: How to onboard a CLL patient in first line treatment?

2020-11-16dr. Snauwaert Sylvia
Hematologie

Waldenström’s macroglobulinemia and renal insufficiency: a case report.

2020-02-14dr. Snauwaert Sylvia
Hematologie

Clinical Outcomes with Single-Agent ibrutinib for relapsed/refractory mantle cell lymphoma: IA of the Belgian Ibrutinib Real-World Data (BiRD) Study.

dr. Snauwaert Sylvia
Hematologie

Effectiveness and safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: IA of the Belgian Ibrutinib Real-World Data (BiRD) Study.

dr. Snauwaert Sylvia
Inwendige Ziekten

20th Post-ASH Meeting.

Brusseldr. Snauwaert Sylvia